In collaboration with Dr. In-San Kim from the Korea Institute of Science and Technology, the 2nd K-DOC Science Online Conference (K-SOC) was held on January 20, 2022, focusing on the theme of 'Extracellular Vesicles and Exosome-Based Therapeutics'. This conference featured participation from world-renowned scholars who discussed a variety of topics related to therapeutics centered on extracellular vesicles and exosomes. Notably, speakers included Professor Kenneth Witwer from Johns Hopkins, Editor-in-Chief of the Journal of Extracellular Biology Andrew Hill, Professor Joy Wolfram from the University of Queensland, and Professor Matthew Wood from Oxford University, founder of the exosome drug development company 'Evox'.
Exosomes, produced by our body's cells and naturally equipped with various biological factors, can function as 'avatars of the cell', sparking increasing interest in the research and clinical trials within the field of extracellular vesicles and exosomes. This international academic conference is expected to explore the latest trends in the exosome field, considered a next-generation innovative drug development approach, and provide extensive opportunities for academic exchange.
Dr. In-San Kim stated, "We aim to gather global researchers to share insights on the utilization of exosomes in addressing unmet medical needs."
In collaboration with Dr. In-San Kim from the Korea Institute of Science and Technology, the 2nd K-DOC Science Online Conference (K-SOC) was held on January 20, 2022, focusing on the theme of 'Extracellular Vesicles and Exosome-Based Therapeutics'. This conference featured participation from world-renowned scholars who discussed a variety of topics related to therapeutics centered on extracellular vesicles and exosomes. Notably, speakers included Professor Kenneth Witwer from Johns Hopkins, Editor-in-Chief of the Journal of Extracellular Biology Andrew Hill, Professor Joy Wolfram from the University of Queensland, and Professor Matthew Wood from Oxford University, founder of the exosome drug development company 'Evox'.
Exosomes, produced by our body's cells and naturally equipped with various biological factors, can function as 'avatars of the cell', sparking increasing interest in the research and clinical trials within the field of extracellular vesicles and exosomes. This international academic conference is expected to explore the latest trends in the exosome field, considered a next-generation innovative drug development approach, and provide extensive opportunities for academic exchange.
Dr. In-San Kim stated, "We aim to gather global researchers to share insights on the utilization of exosomes in addressing unmet medical needs."